Combination therapy with depantol and lavomax for diseases of the cervix uteri


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

It is important to develop more effective methods for diagnosis and combination therapy, which are aimed at accelerating the processes of cervical epithelial regeneration and at preventing cancer of the cervix uteri (CCU) in the presence of human papillomavirus (HPV) infection. Objective: to study the therapeutic efficacy of the immunomodulator lavomax and depantol vaginal suppositories, which stimulate tissue epithelialization after damage, in order to improve management tactics for women with HPV-associated genital lesions and for those with the symptoms of cervicitis in the presence of cervical ectopy. Subjects and methods. The comparative randomized investigation enrolled 80 patients aged 18 to 50 years; their follow-up lasted 6 months. Clinical, laboratory, and instrumental findings and evaluated the efficiency and safety of treatment with above mentioned agents versus the conventional clinical tactics were analyzed. Results. Incorporation of lavomax and depantol into the combination therapy of papillomavirus-associated diseases of the cervix uteri in combination of destruction of the abnormal epithelium significantly exceeds therapeutic effectiveness versus monoablation. Depantol therapy for chronic cervicitis in the presence of ectopy and immature metaplasia significantly improves its clinical picture as evidenced by colposcopy, cytology, subjective complaints versus passive follow-up tactics. Conclusion. The traditional treatment regimens for patients with HPV-associated cervical diseases should include lavomax (7 days before cervical destruction: as a 125-mg tablet once daily in the first two days, after a one-day interval at the same dosage: a course dosage of 125-mg tablets once daily for 20 days, also after two weeks: one depantol suppository twice daily for 10 days. Women with chronic slowly progressive cervicitis in the presence of ectopy and an extensive transformation area with no signs of dysplasia should use depantol by the scheme: one suppository twice daily for 20 days.

Full Text

Restricted Access

About the authors

Svetlana Ivanovna Rogovskaya

Russian Medical Academy of Postgraduate Education

Email: srogovskaya@mail.ru
MD, professor of the Department of Obstetrics and Gynecology

Lyudmila Aleksandrovna Terebneva

Russian Medical Academy of Postgraduate Education

postgraduate student of the Department of Obstetrics and Gynecology

Natalya Mikhaylovna Podzolkova

Russian Medical Academy of Postgraduate Education

MD, professor, Head of the Department of Obstetrics and Gynecology

References

  1. Роговская С.И., Акопова Е.С., Коган Е.А. Совершенствование лечебно-диагностических подходов к ВПЧ-инфекции гениталий. Русский медицинский журнал. 2011; 20: 1238-42. [Rogovskaya S.I., Akopova E.S., Kogan E.A. Improvement of diagnostic and treatment approaches to HPV infection of genitals. RMJ. 2011; 20: 1238-42.]
  2. Довлетханова Э.Р., Абакарова П.Р Возможности комплексного лечения хронических цервицитов. Акушерство и гинекология. 2012; 4(1): 83-6. [Dovletkhanova E.R., Abakarova P.R. Possibilities of combination treatment for chronic cervicitis. Obstetrics and Gynecology. 2012; 4(1): 83-6.]
  3. Роговская С.И., Бебнева Т.Н. Доброкачественные заболевания и состояния шейки матки. В кн.: Роговская С.И., Липова Е.В., ред. Шейка матки, влагалище, вульва. Физиология, патология, кольпоскопия, эстетическая коррекция. М.: StatusPraesens; 2014. [Rogovskaya S.I., Bebneva T.N. Benign diseases and states of cervix uteri. In: Rogovskaya S.I., Lipova E.V., eds. Cervix uteri, vagina, and vulva. Physiology, pathology, colposcopy, aesthetic correction. M.: StatusPraesens; 2014.]
  4. Зуйкова И.Н., Шульженко А.Е. Персистирующая папилломави-русная инфекция: цитокиновый дисбаланс и подходы к терапии. Эффективная фармакотерапия. Акушерство и гинекология. 2013; 2: 54-60. [Zuykova I.N., Shulzhenko A.E. Persisting pappilomavirus infection: cytokine imbalance and approaches to the therapy. Effective pharmacotherapy. Obstetrics and gynecology. 2013; 2: 54-60.]
  5. Роговская С.И., Теребнева Л.И. Клинические аспекты плоскоклеточных интраэпителиальных поражений низкой степени. Акушерство и гинекология. 2013; 2: 136-43. [Rogovskaya S.I., Terebneva L.I. Clinical aspects of low-grade squamous intraepithelial lesions. Obstetrics and Gynecology. 2013; 2: 136-43.]
  6. HPV treatment guidlines. Available at: www.cdc.govstdtreatment6-2010
  7. Poljak M., Rogovskaya S.I., Kesić V., Bray F., Berkhof J., Seme K. et al. Recommendations for cervical cancer pevention in Central and Eastern Europe and Central Asia. Vaccine. 2013; 31(Suppl. 7): H80-2.
  8. Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y. et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine. 2013; 31(Suppl. 7): H46-58.
  9. Wright T.C. Jr., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am. J. Obstet. Gynecol. 2007; 197(4): 340-5.
  10. Jordan J., Martin-Hirsch P., Arbyn M., Schenck U., Baldauf J.J., Da Silva D. et al. European guidelines for clinical management of abnormal cervical cytology. Part 2. Cytopathology. 2009; 20(1): 5-16.
  11. Сухих Г.Т., Прилепская В.Н., Роговская С.И., Бебнева Т.Н., Межевитинова Е.А., Петрунин Д.Д. Применение препаратов интерферона при лечении плоскоклеточных поражений шейки матки низкой степени. З турботою про жінку (Київ). 2012; 8: 10-2. [Sukhikh G.T., Prilepskaya V.N., Rogovskaya S.I., Bebneva T.N., Mezhevitinova E.A., Petrunin D.D. Application of interferon drugs during the treatment of low grade squamous intraepithelial lesions of cervix uteri. Z turbatoyu pro zhinku (Kiev). 2012; 8: 10-2.]
  12. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 2003; 188(6): 1393-400.
  13. Schöfer H., Van Ophoven A., Henke U., Lenz T., Eul A. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur. J. Dermatol. 2006; 16(6): 642-8.
  14. Herdman M.T., Pett M.R., Roberts I., Alazawi W.O., Teschendorff A.E., Zhang X.Y. et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis. 2006; 27(11): 2341-53.
  15. Grimm C., Polterauer S., Natter C., Rahhal J., Hefler L., Tempfer C.B. et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet. Gynecol. 2012; 120(1): 152-9.
  16. Кузнецова И.В., Сулейманова Н.С. Применение иммуномодуляторов в терапии цервицита. Акушерство и гинекология. 2014; 2: 80-5. [Kuznetsova I.V., Suleimanova N.S. Use of immunomodulators in the therapy of cervicitis. Obstetrics and Gynecology. 2014; 2: 80-5.]
  17. Пекарев О.Г., Вишнякова С.В. Реабилитационная терапия последеструктивных воздействий на шейке матки. Вопросы гинекологии, акушерства и перинатологии. 2010; 9(3): 72-6. [Pekarev O.G., Vishnyakova S.V. Occupational therapy after destructive effects on the cervix uteri. Questions gynecology, obstetrics and perinatology. 2010; 9 (3): 72-6.]
  18. Вдовин С.В., Селихова М.С., Филина Е.В., Сперанский Д.Л., Селихов А.В. Особенности ведения послеоперационного периода у пациенток с пролапсом гениталий. Саратовский научно-медицинский журнал. 2012; 8(1): 047-050. [Vdovin S.V., Selikhova M.S., Filina E.V., Speranskiy D.L., Selihov A.V. Particuliarities of post-operative period maintenance with patients with genitalia prolapse. Saratov Journal of Medical Scientific. 2012; 8 (1): 047-050.]
  19. Подзолкова Н.М., Роговская С.И., Минкина Г.Н., Короленкова Л.И., Акопова Е.С. Новое в кольпоскопии. Гинекология. 2011; 13(6): 20-5. [Podzolkova N.M., Rogovskaya S.I., Minkina G.N., Korolenkova L.I., Akopova ES New in Новое в colposcopy. Gynecology. 2011; 13 (6): 20-5.]
  20. Мальцева Л.И. Опыт применения препарата «Депантол», суппозитории вагинальные, после лазерной коагуляции или криодеструкции шейки матки. Пресс-релиз. Available at: www.medi.ru. [Maltseva L.I. Experiment of Depanthenol drug application, vaginal suppositories, after the lazer coagulation or cryolysis of the cervix uteri. Press-release. Available at: www.medi.ru.]
  21. Подзолкова Н.М., Роговская С.И., Фадеев И.Е., Ардус Ф.С. Папилломавирусная инфекция: что нового? Гинекология. 2011; 13(5): 39-45. [Podzolkova N.M., Rogovskaya S.I., Fadeev I.E., Ardus F.S. Pappilomavirus infection: what’s new? Gynecology. 2011; 13 (5): 39-45.]
  22. Минкина Г.Н., Калинина В.С., Гаврикова М.В., Фириченко С.В., Храмова О.К. Постлечебный мониторинг цервикальных интраэпителиальных неоплазий. Журнал акушерства и женских болезней. 2011; 60(1): 109-13. [Minkina G.N., Kalinina V.S., Gavrikova M.V., Firichenko S.V., Khramova D.C. Post-treatment monitoring of cervical intraepithelial neoplasia. Journal of Obstetrics and women’s diseases. 2011; 60 (1): 109-13.]
  23. Снисаренко Е.А., Коваленко И.А. Опыт применения препарата Лавомакс в комплексном лечении папилломавирусной инфекции. Фарматека. 2007; 10: 72-7. [Snisarenko E.A., Kovalenko I.A. Experience of drug Lavomax in treatment of human papillomavirus infection. Farmateka. 2007; 10: 72-7.].
  24. Радзинский В.Е., Петрова В.Д., Хамошина М.Б., Салимова Л.Я., Руднева О.Д., Архипова М.П., Строни Р. Оптимизация заживления раны после пластических хирургических операций. Акушерство и гинекология. 2011; 1: 89-94. [Radzinsky V.E., Petrova V.D., Khamoshina M.B., Salimova L.Ya., Rudneva O.D., Arkhipova M.P., Stroni R. Optimization of wound healing after plastic surgery. Obstetrics and Gynecology. 2011; 1: 89-94.]
  25. Лавомакс таблетки, покрытые оболочкой. Инструкция по медицинскому применению препарата Р N003749/01. [Lavomax of coated tablets. Instruction for medical use of the drug Р N003749/01].
  26. Ijazović E., Ljuca D., Sahimpasić A., Avdić S. Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions. Bosn. J. Basic Med. Sci. 2006; 6(4): 79-84.
  27. Machado F.A., Janssens J.P., Michelin M.A., Murta E.F. Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix. Clin. Exp. Obstet. Gynecol. 2012; 39(1): 27-31.
  28. Seresini S., Origoni M., Lillo F., Caputo L., Paganoni A.M., Vantini S. et al. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J. Immunol. 2007; 179(10): 7176-83.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies